CD274 and neoplasm: Currently, anti-PD-1/PD-L1 antibodies are used for systematic treatment, which is based on the principle that PD-1 monoclonal antibodies activate functionally depleted T cells by blocking the immunosuppressive response mediated by the PD-1 pathway, recovering the tumor-killing effect of T cells.38